Results from LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to…

[unable to retrieve full-text content]


More:  NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA® LAUNCHED IN JAPAN | News Release:2020

More from: | Category: Pharmaceutical Company News